No abstract

No abstract

Background: Several cytokines are known to be involved in the pathogenesis of non-Hodgkin Lymphomas (NHL). Aim: Given the importance of understanding the genetic predisposition involved in the pathogenesis of NHL, this work was designed to study the impact of IL-10 (-1082 G/A; rs1800896 and -819 C/T; rs1800871), IL-6 (-174 G/C; rs1800795) and CD38 (184C/G; rs6449182) gene polymorphisms on the susceptibility of Egyptians to NHL. Materials and Methods: Both loci of IL10 were genotyped using polymerase chain reaction-sequence-specific primers (PCR-SSP), IL6 rs1800795 G/C was genotyped using mutagenically separated PCR (MS-PCR) and restriction fragment length polymorphism-PCR (RFLP-PCR) was used to genotype CD38 (rs6449182 C/G) in 100 Egyptian patients and 119 controls. Plasma levels of IL-6 and IL-10 were measured using enzyme-linked immunosorbent assay (ELISA). Results: An insignificant change in IL-10 (rs1800896 and rs1800871) genotypes were recorded. GT haplotype was significantly elevated. Conclusion: Lymphoma samples express a particular polymorphism.

Background: The aim of this phase II clinical study was to evaluate three-weekly docetaxel plus prednisolone as firstline chemotherapy for treatment of hormone-refractory metastatic prostate cancer (HRMPC). Materials and Methods: Thirty five metastatic HRPC patients were treated with docetaxel 70 mg/m2 on Day 1, every 3 weeks plus oral prednisolone 5 mg twice daily at Clinical Oncology Departments, Tanta, Mansoura and Menofia University Hospitals during the period from June 2006 to December 2008. The primary endpoint was assessment of the overall tumor response rate. Secondary endpoints were assessment of PSA response rate, overall survival rate and the time to disease progression. Results: In 35 patients with metastatic HRPC, the median number of cycles administered was 6 cycles. Partial response was observed in 15 patients (42.9%) with evaluable measurable disease. Median survival from protocol entry was 12 months. Median time to disease progression was 9 months. Prostate-specific antigen (PSA) declined ≥50% in 9 patients (25.7%). The most common grade 34/ toxicity associated with studied protocol was neutropenia (85.7%). Conclusions: When given with prednisolone, treatment with docetaxel every three weeks lead to improved survival and response rates with accepted tolerability.

No abstract